Cefepime

What is Cefepime?

Cefepime is a powerful, broad-spectrum antibiotic belonging to the fourth-generation cephalosporin class. It is primarily used to treat a wide range of serious bacterial infections, particularly those acquired in hospital settings or those resistant to other antibiotics. Administered parenterally, typically intravenously, Cefepime is a critical tool in managing severe infections such as pneumonia, complicated urinary tract infections, and intra-abdominal infections, especially when caused by multi-drug resistant Gram-negative bacteria.

As an antibacterial for systemic use, Cefepime is classified under the ATC code J01 (Antibacterial for systemic use), specifically J01DE01. Its unique structure provides enhanced stability against hydrolysis by a wide array of beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) produced by certain Gram-negative bacteria. This characteristic makes Cefepime an essential agent for empiric therapy in critically ill patients, particularly those with febrile neutropenia, where rapid and effective broad-spectrum coverage is crucial.

Mechanism of Action

Cefepime exerts its bactericidal effect by interfering with bacterial cell wall synthesis. Like other beta-lactam antibiotics, it targets and inactivates specific enzymes known as penicillin-binding proteins (PBPs) located on the inner bacterial cell membrane. These PBPs are crucial for the final stages of peptidoglycan synthesis, a vital component of the bacterial cell wall.

• Cefepime penetrates the bacterial outer membrane and binds irreversibly to various penicillin-binding proteins (PBPs), particularly PBP-2 and PBP-3.
• This binding inhibits the transpeptidation step of peptidoglycan synthesis, which is essential for cross-linking the peptidoglycan strands.
• The disruption of peptidoglycan synthesis weakens the bacterial cell wall, leading to increased osmotic pressure within the cell.
• Ultimately, this results in bacterial lysis and cell death, demonstrating its potent bactericidal activity.
• Cefepime's unique structure provides enhanced resistance to hydrolysis by many common beta-lactamases, allowing it to remain effective against a broader spectrum of bacteria compared to earlier generation cephalosporins.

Medical Uses

Primary Uses:

• Complicated Urinary Tract Infections (cUTI), including pyelonephritis
• Complicated Intra-abdominal Infections (cIAI) (often in combination with metronidazole)
• Pneumonia, including moderate to severe nosocomial pneumonia
• Empiric therapy for Febrile Neutropenia
• Skin and Soft Tissue Infections (SSTI)

Secondary Uses:

• Bacteremia associated with any of the primary indications
• Meningitis (in specific cases, particularly in children and adults with susceptible organisms)
• Bone and Joint Infections (when susceptible organisms are identified)

Dosage

The dosage of Cefepime varies depending on the severity of the infection, the patient's renal function, and the specific indication. It is crucial to adjust the dosage in patients with impaired renal function to prevent accumulation and potential adverse effects.

Side Effects

While generally well-tolerated, Cefepime can cause side effects. Patients should be monitored for any adverse reactions during treatment.

Common Side Effects:

• Diarrhea
• Nausea and Vomiting
• Headache
• Rash or itching
• Injection site reactions (pain, inflammation)
• Abnormal liver function tests (transient elevations)

Rare but Serious Side Effects:

• Clostridioides difficile-associated diarrhea (CDAD), which can range from mild diarrhea to fatal colitis
• Neurotoxicity, including seizures, encephalopathy, myoclonus, and nonconvulsive status epilepticus, particularly in patients with renal impairment who receive unadjusted doses of Cefepime
• Severe hypersensitivity reactions, including anaphylaxis and Stevens-Johnson syndrome
• Hemolytic anemia
• Thrombocytopenia or leukopenia

Warnings

Contraindications:

Cefepime is contraindicated in individuals with a known history of hypersensitivity to Cefepime, other cephalosporin antibiotics, penicillins, or any other beta-lactam antibiotics. A history of severe hypersensitivity reaction to any beta-lactam is a strict contraindication due to the risk of cross-reactivity.

Patients with pre-existing renal impairment require careful dose adjustment of Cefepime to prevent drug accumulation and the increased risk of neurotoxicity. Close monitoring of renal function and neurological status is essential throughout therapy. As with all antibiotics, prolonged use of Cefepime may result in the overgrowth of non-susceptible organisms, necessitating careful patient monitoring and appropriate intervention.

This article provides general medical information and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health or treatment.